TCM Biotech International Corp. (TPEX:4169)
Taiwan · Delayed Price · Currency is TWD 186.00
+2.50 (1.36%)
Jan 22, 2026, 10:16 AM CST
TCM Biotech International Revenue
TCM Biotech International had revenue of 172.66M TWD in the quarter ending September 30, 2025, with 4.84% growth. This brings the company's revenue in the last twelve months to 682.40M, down -8.63% year-over-year. In the year 2024, TCM Biotech International had annual revenue of 666.53M, down -31.26%.
Revenue (ttm)
682.40M
Revenue Growth
-8.63%
P/S Ratio
15.88
Revenue / Employee
n/a
Employees
n/a
Market Cap
10.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 666.53M | -303.09M | -31.26% |
| Dec 31, 2023 | 969.62M | 167.20M | 20.84% |
| Dec 31, 2022 | 802.42M | 100.38M | 14.30% |
| Dec 31, 2021 | 702.05M | -35.03M | -4.75% |
| Dec 31, 2020 | 737.08M | 168.45M | 29.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEngine | 2.51B |
| Adimmune | 1.20B |
| Ever Supreme Bio Technology | 1.01B |
| Mycenax Biotech | 649.64M |
| TaiMed Biologics | 607.22M |
| Medigen Vaccine Biologics | 594.96M |
| Tanvex BioPharma | 224.83M |
| TaiGen Biopharmaceuticals Holdings | 38.75M |